Vistagen Therapeutics Notifies Nasdaq of Audit Committee Non-Compliance

summarizeSummary

Vistagen Therapeutics, Inc. reported non-compliance with Nasdaq's Audit Committee composition rule following a director's resignation, though its listing is not immediately affected.

check_boxKey Events

• Nasdaq Non-Compliance Notified

  Vistagen Therapeutics formally notified Nasdaq of its non-compliance with Listing Rule 5605(c)(2), which requires a minimum of three independent directors on the Audit Committee.

• Director Resignation Impact

  The non-compliance resulted from Ms. Mary Rotunno's resignation from the Board, effective April 1, 2026, reducing the Audit Committee to two members.

• Cure Period Granted

  The company has been granted a cure period to regain compliance, and its common stock listing on The Nasdaq Capital Market is not immediately affected by this specific non-compliance.

• Context of Existing Distress

  This governance issue arises while the company is already facing substantial doubt about its ability to continue as a going concern and a broader Nasdaq delisting threat, as previously reported in its last 10-Q.

auto_awesomeAnalysis

This 8-K filing indicates Vistagen Therapeutics is facing another governance challenge, formally notifying Nasdaq of its non-compliance with the rule requiring at least three independent directors on its Audit Committee. This issue stems from a recent director resignation. While the company has a cure period and its listing is not immediately threatened by this specific non-compliance, it adds to the existing concerns about the company's ability to continue as a going concern and its broader Nasdaq delisting threat, as previously disclosed in its last 10-Q. Investors should monitor the company's progress in regaining compliance and its overall financial stability.